Minerva Neurosciences (NERV)
NASDAQ:NERV
NERV Stock Chart & Stats
$6.14
-$0.09(-3.83%)
At close: 4:00 PM EST
$6.14
-$0.09(-3.83%)
Day’s Range― - ―
52-Week Range$1.15 - $12.46
Previous CloseN/A
Volume1.19K
Average Volume (3M)465.60K
Market Cap
$265.70M
Enterprise Value$25.60M
Total Cash (Recent Filing)$82.30M
Total Debt (Recent Filing)$64.96M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding43,274,400
10 Day Avg. Volume1,362,901
30 Day Avg. Volume465,600
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.41K
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$7.00Price Target Upside14.01% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.79
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy Signal And KOL SupportAnalyst points to the observed efficacy signal for roluperidone and key opinion leader endorsement as strengthening the case for benefit on negative symptoms and potential clinician interest.
Funding FlexibilityAnalyst highlights secured financing and a registration shelf that provide flexibility to fund the late-stage program and support study progress.
Regulatory AlignmentAnalyst notes alignment with the FDA on the late-stage clinical design, which increases the likelihood that the drug could gain approval as a monotherapy for patients with prominent negative symptoms of schizophrenia.
Bears Say
Comparative Efficacy UncertaintyAnalyst notes that the planned descriptive comparison to standard antipsychotic treatment, without a formal non-inferiority test, leaves uncertainty about long-term comparative efficacy and safety when used alone.
Execution Risk From Prior TrialAnalyst warns that a prior late-stage study failed to meet its primary endpoint due to patient quality and variability issues, creating execution risk for the ongoing program.
Pivotal Endpoint RiskAnalyst cautions that reliance on the personal and social functioning scale as a pivotal measure raises trial risk if results are not clearly positive, which could affect regulatory assessment.
Minerva Neurosciences News
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.15 and its highest was $12.46 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is $265.70M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is May 06, 2026 which is in 40 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Mar 11, 2026. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.302 by -$0.338.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -0.13.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 43,274,400 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.302. Following the earnings report the stock price went down -8.06%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Minerva Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.48%
12-Months-Change
Fundamentals
Return on Equity
506.72%
Trailing 12-Months
Asset Growth
163.76%
Trailing 12-Months
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
NERV Stock 12 Month Forecast
Average Price Target
$7.00
▲(14.01% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Pulmatrix
―
Chemomab Therapeutics
―
―
Aspire Biopharma Holdings
―
Ownership Overview
1.10%
Insiders
3.39% Mutual Funds
39.13% Other Institutional Investors
55.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---